Related Articles
Metabolism‑related pharmacokinetic drug‑drug interactions with poly (ADP‑ribose) polymerase inhibitors (Review)
PARP inhibitors and epithelial ovarian cancer: Molecular mechanisms, clinical development and future prospective (Review)
Candidate synthetic lethality partners to PARP inhibitors in the treatment of ovarian clear cell cancer (Review)
Novel insight into the function of tankyrase (Review)
Poly(ADP-ribose) polymerase, a potential target for drugs: Cellular regulatory role of the polymer and the polymerase protein mediated by catalytic and macromolecular colligative actions (Review).